I think FDA's concerns are patient-safety.
I have targets for business achievements; I do not have targets for acquisitions. Because if you have targets for acquisitions, you end up making compromises in terms of valuations, and you buy things because you have a target, and it is not good for business.
Our focus is to see that we are growing faster than the industry and, whichever product we launch, we do better than competition. We try and manage our operations better than competition. Essentially, we try to be better than what we were the previous year.
Sun is seeking some products that we don't have or technologies that we don't have.
Sun Pharma's relationship with AML is on an arm's-length basis. As investors have expressed concerns regarding this arrangement, we are in the process of evaluating various options for undertaking domestic formulation business.
The Ranbaxy acquisition doesn't preclude us from making more large acquisitions. The important issue is whether we have the management bandwidth to handle the acquisition.
The reason we don't give a date by which we will acquire something is because we don't want to create pressure on ourselves to buy something.
